Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: BELFA stock price vs CI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at CI's multiple
Needs Annual EPS, CI P/E.
Implied fair value · at BELFA's multiple
Needs BELFA P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
BEL FUSE INC /NJ · implied price per share
A valid share-count denominator is required for the selected valuation policy.
The Cigna Group · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
TE Connectivity plc
BELFA vs TEL
APPLIED MATERIALS INC /DE
BELFA vs AMAT
LITTELFUSE INC /DE
BELFA vs LFUS
ALASKA AIR GROUP, INC.
BELFA vs ALK
AMPHENOL CORP /DE/
BELFA vs APH
VISHAY INTERTECHNOLOGY INC
BELFA vs VSH
UNITEDHEALTH GROUP INC
BELFA vs UNH
CVS HEALTH Corp
BELFA vs CVS
HUMANA INC
BELFA vs HUM
CENTENE CORP
BELFA vs CNC
WEST PHARMACEUTICAL SERVICES INC
BELFA vs WST
BAXTER INTERNATIONAL INC
BELFA vs BAX
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe BELFA can sustain its superior margins and 26.3% revenue growth, then a bullish stance is justified because the stock is cheaper on P/E than CI while also carrying lower leverage and stronger quality signals.
BELFA appears undervalued relative to CI on an earnings basis, with a P/E of 8.1x versus CI at 13.0x and an implied upside of 59.5% to $367.09 from the current $230.20 price. The valuation signal is supported by stronger operating metrics at BELFA, though the stock already sits above the midpoint of its historical band.
Supporting Metrics
